Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Atherosclerosis

• Publication date

  2001-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0021-9150(00)00714-0PMID 11427209
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of cholesterol ester mass in regulation of secretion of ApoB100 lipoprotein particles by hamster hepatocytes and effects of statins on that relationship.

  1999cited by this paper
• Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.

  1999cited by this paper
• Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.

  1998cited by this paper
• Transcriptional regulation of muscle-specific genes during myoblast differentiation.

  1998cited by this paper
• Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.

  1998cited by this paper
• Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

  1998cited by this paper
• An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits.

  1998cited by this paper
• The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.

  1998cited by this paper
• A brief review paper of the efficacy and safety of atorvastatin in early clinical trials.

  1997cited by this paper
• Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

  1997cited by this paper
• A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.

  1997cited by this paper
• A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

  1997cited by this paper
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion.

  1997cited by this paper
• Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.

  1997cited by this paper
• Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

  1996cited by this paper
• Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig.

  1996cited by this paper
• Real time quantitative PCR.

  1996cited by this paper
• Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

  1996cited by this paper
• ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools.

  1996cited by this paper
• Microsomal triacylglycerol transfer protein prevents presecretory degradation of apolipoprotein B-100. A dithiothreitol-sensitive protease is involved.

  1996cited by this paper
• Role of cholesterol in regulating apolipoprotein B secretion by the liver.

  1996cited by this paper
• Hepatic Expression of the Catalytic Subunit of the Apolipoprotein B mRNA Editing Enzyme (apobec-1) Ameliorates Hypercholesterolemia in LDL Receptor-Deficient Rabbits

  1996cited by this paper
• Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression.

  1995cited by this paper
• Role of the neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells.

  1995cited by this paper
• Nascent VLDL phospholipid composition is altered when phosphatidylcholine biosynthesis is inhibited: evidence for a novel mechanism that regulates VLDL secretion.

  1995cited by this paper
• Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.

  1995cited by this paper
• Evaluation of cultured hamster hepatocytes as an experimental model for the study of very low density lipoprotein secretion.

  1995cited by this paper
• Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

  1995cited by this paper
• Exogenous VLDL stimulates apolipoprotein B secretion from HepG2 cells by both pre- and post-translational mechanisms.

  1994cited by this paper
• Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester.

  1994cited by this paper
• Regulated intracellular degradation of apolipoprotein B in semipermeable HepG2 cells.

  1994cited by this paper
• Lipid balance in HepG2 cells: active synthesis and impaired mobilization.

  1994cited by this paper
• Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts.

  1993cited by this paper
• An inhibitor of squalene epoxidase, NB-598, suppresses the secretion of cholesterol and triacylglycerol and simultaneously reduces apolipoprotein B in HepG2 cells.

  1993cited by this paper
• Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells.

  1993cited by this paper
• Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes.

  1993cited by this paper
• An inhibitor of squalene epoxidase, NB-598, suppresses the secretion of cholesterol and triacylglycerol and simultaneously reduces apolipoprotein B in HepG2 cells.

  1993cited by this paper
• The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoprotein B gene expression in HepG2 cells.

  1992cited by this paper
• Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia.

  1992cited by this paper
• Cholesterol metabolism in cultured hamster hepatocytes.

  1992cited by this paper
• Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.

  1990cited by this paper
• Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.

  1990cited by this paper
• Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells

  1990cited by this paper
• Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge.

  1990cited by this paper
• Purification and characterization of microsomal triglyceride and cholesteryl ester transfer protein from bovine liver microsomes.

  1985cited by this paper
• Evidence for separate pathways of chylomicron and very low-density lipoprotein assembly and transport by rat small intestine.

  1984cited by this paper
• Receptor-mediated endocytosis of low-density lipoprotein in cultured cells.

  1983cited by this paper
• Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

  1980cited by this paper

• High-fat diet induced alterations in plasma membrane cholesterol content impairs insulin receptor binding and signalling in mouse liver but is ameliorated by atorvastatin.

  2022cites this paper
• Oxidative Modification of Lipoproteins: A Potential Role of Oxidized Small dense LDL in Enhanced Atherogenicity

  2021cites this paper
• The Impact of Rheohaemapheresis on the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) in Age-Related Macular Degeneration

  2020cites this paper
• Stevia: limiting cholesterol synthesis in Hep-G2 cells

  2020cites this paper
• Apolipoprotein A-I Mimetic Peptide L-4F Removes Bruch's Membrane Lipids in Aged Nonhuman Primates.

  2019cites this paper
• Eryngium carlinae Ethanol Extract Corrects Lipid Abnormalities in Wistar Rats with Experimental Diabetes

  2019cites this paper
• Retina Apolipoprotein A-I Mimetic Peptide L-4 F Removes Bruch ’ s Membrane Lipids in Aged Nonhuman Primates

  2019cites this paper
• Soft Drusen in Age-Related Macular Degeneration: Biology and Targeting Via the Oil Spill Strategies

  2018cites this paper
• The Question of a Role for Statins in Age-Related Macular Degeneration

  2018cites this paper
• Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile

  2017cites this paper
• Effects of Tinospora crispa aqueous extract in regulating cholesterol metabolism in human hepatoma cancer cell line (Hep G2)

  2017cites this paper
• MicroRNAs regulating apolipoprotein B-containing lipoprotein production.

  2016cites this paper
• Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice

  2016cites this paper
• Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials.

  2016cites this paper
• The molecular mechanism of the cholesterol‐lowering effect of dill and kale: The influence of the food matrix components

  2016cites this paper
• Anticholesterol activity of anacardium occidentale linn. does it involve in reverse cholesterol transport

  2015cites this paper
• Extraction of a soluble polysaccharide from Auricularia polytricha and evaluation of its anti-hypercholesterolemic effect in rats.

  2015cites this paper
• Atorvastatin Increases miR‐124a Expression: A Mechanism of Gamt Modulation in Liver Cells

  2015cites this paper
• Cholesterol in the retina: the best is yet to come.

  2014cites this paper
• Regulation of diacylglycerol acyltransferase 2 protein stability by gp78‐associated endoplasmic‐reticulum‐associated degradation

  2014cites this paper
• A Review on the Traditional Chinese Medicinal Herbs and Formulae with Hypolipidemic Effect

  2014cites this paper
• Combined Phytosterol and Fish Oil Therapy for Lipid Lowering and Cardiovascular Health

  2014cites this paper
• Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemias.

  2013cites this paper
• A Self Assembling Nanoemulsion of Lovastatin (SANEL) Decreases Cholesterol Accumulation and Apob-100 Secretion Greater than Lovastatin alone a Hepg2 Cell Line

  2012cites this paper
• Therapeutic approaches to drug targets in hyperlipidemia

  2012cites this paper
• Probucol Suppresses Enterocytic Accumulation of Amyloid-β Induced by Saturated Fat and Cholesterol Feeding

  2011cites this paper
• The oil spill in ageing Bruch membrane

  2011cites this paper
• Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.

  2010cites this paper
• Human caspase 7 is positively controlled by SREBP-1 and SREBP-2.

  2009cites this paper
• Beyond blood lipids: phytosterols, statins and omega-3 polyunsaturated fatty acid therapy for hyperlipidemia.

  2009cites this paper
• Statins as effectors of key activities involved in apoE-dependent VLDL metabolism: review and hypothesis.

  2008cites this paper
• Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease

  2007cites this paper
• The effect of high-dose simvastatin on free fatty acid metabolism in patients with type 2 diabetes mellitus.

  2006cites this paper
• A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients

  2006cites this paper
• Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis.

  2006cites this paper
• Epigallocatechin gallate increases the formation of cytosolic lipid droplets and decreases the secretion of apoB-100 VLDL Published, JLR Papers in Press, October 14, 2005.

  2006cites this paper
• The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus Published, JLR Papers in Press, October 28, 2005.

  2006cites this paper
• Endotoxin promotes preferential periportal upregulation of VLDL secretion in the rat liver Published, JLR Papers in Press, February 16, 2005. DOI 10.1194/jlr.M500003-JLR200

  2005cites this paper
• Influence of microsomal triglyceride transfer protein promoter polymorphism −493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia

  2005cites this paper
• Post-transcriptional regulation of apoC-I synthesis and secretion in human HepG2 cells.

  2005cites this paper
• Statin Induction of Liver Fatty Acid-Binding Protein (L-FABP) Gene Expression Is Peroxisome Proliferator-activated Receptor-α-dependent*

  2004cites this paper
• Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9

  2004cites this paper
• Familial hypercholesterolemia--improving treatment and meeting guidelines.

  2003cites this paper
• Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes Published, JLR Papers in Press, October 16, 2002. DOI 10.1194/jlr.M200316-JLR200

  2003cites this paper
• Dual action of neutral sphingomyelinase on rat hepatocytes: Activation of cholesteryl ester metabolism and biliary cholesterol secretion and inhibition of VLDL secretion

  2003cites this paper
• Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model.

  2003cites this paper
• Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats.

  2002cites this paper
• Familial combined hyperlipidemia plasma stimulates protein secretion by HepG2 cells: identification of fibronectin in the differential secretion proteome.

  2002cites this paper
• Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2)

  2002cites this paper
• Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.

  2002cites this paper
• Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor.

  2002cites this paper